WO2025079564A1 - タンパク質試料の調製方法、核酸のライゲーション方法、ngsライブラリの調製方法、及びキット - Google Patents
タンパク質試料の調製方法、核酸のライゲーション方法、ngsライブラリの調製方法、及びキット Download PDFInfo
- Publication number
- WO2025079564A1 WO2025079564A1 PCT/JP2024/035866 JP2024035866W WO2025079564A1 WO 2025079564 A1 WO2025079564 A1 WO 2025079564A1 JP 2024035866 W JP2024035866 W JP 2024035866W WO 2025079564 A1 WO2025079564 A1 WO 2025079564A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- derived
- nucleic acid
- ligase
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
Definitions
- the present disclosure relates to a method for preparing a protein sample, a method for ligating nucleic acids, a method for preparing an NGS library, and a kit.
- Proteins used in biotechnology research, diagnosis, and pharmaceuticals are often cell-derived proteins obtained by intracellular synthesis and purification.
- cell-derived proteins may be contaminated with not only the target protein, but also cell-derived DNA, etc.
- Cell-derived DNA, etc. may cause problems such as inhibiting the activity of the target protein or causing side reactions.
- nucleic acids e.g., DNA or RNA, etc.
- cell-derived DNA, etc. become contaminants and are likely to cause side reactions.
- next-generation sequencers Next-Generation Sequencing (NGS)
- NGS Next-Generation Sequencing
- Patent Document 1 discloses a method for removing DNA impurities from a sample containing a target protein by making the sample into a low-conductivity aqueous solution with a pH lower than the isoelectric point of the protein and filtering the resulting particles.
- Patent Documents 2 and 3 disclose methods for removing nucleic acids by processing a sample containing a target protein with a filter under specific conditions.
- Patent Document 1 Japanese Patent No. 5525118 Patent Document 2: Japanese Patent Application Publication No. 11-333259 Patent Document 3: Japanese Patent Application Publication No. 7-133290
- Patent Documents 1 to 3 have problems in that they require large-scale equipment, are complicated to operate, and are costly and time-consuming. Furthermore, although the methods described in Patent Documents 1 to 3 are suitable for purifying a large amount of protein on an industrial scale, they are difficult to scale down and are not suitable for purifying a small amount of protein. In view of the above circumstances, the present disclosure provides a method for preparing a protein sample, a method for ligating nucleic acid, a method for preparing an NGS library, and a kit, which can simply and easily stabilize the quality of a cell-derived protein.
- ⁇ 1> A method for preparing a protein sample, comprising contacting a cell-derived protein with a methylated DNA enzyme.
- ⁇ 2> The method for preparing a protein sample according to ⁇ 1>, wherein the methylated DNA decomposition enzyme is at least one selected from the group consisting of DpnI, McrBC, MspJI, FspEI, LpnPI, and AbaSI.
- ⁇ 3> The method for preparing a protein sample according to ⁇ 1>, wherein the methylated DNA decomposition enzyme is DpnI.
- ⁇ 4> The method for preparing a protein sample according to any one of ⁇ 1> to ⁇ 3>, wherein the cell-derived protein is an Escherichia coli-derived protein.
- ⁇ 5> The method for preparing a protein sample according to any one of ⁇ 1> to ⁇ 3>, wherein the cell-derived protein is an enzyme derived from a cell.
- ⁇ 6> The method for preparing a protein sample according to any one of ⁇ 1> to ⁇ 3>, wherein the cell-derived protein is a cell-derived T4 RNA ligase.
- a method for ligating nucleic acids comprising: contacting a cell-derived nucleic acid ligase with a methylated DNA degrading enzyme; and ligating a second nucleic acid to a first nucleic acid using the cell-derived nucleic acid ligase contacted with the methylated DNA degrading enzyme.
- the methylated DNA enzyme is at least one selected from the group consisting of DpnI, McrBC, MspJI, FspEI, LpnPI, and AbaSI.
- ⁇ 9> The method for ligating nucleic acids according to ⁇ 7>, wherein the methylated DNA enzyme is DpnI.
- ⁇ 10> The method for ligating nucleic acids according to any one of ⁇ 7> to ⁇ 9>, wherein the cell-derived nucleic acid ligase is an Escherichia coli-derived nucleic acid ligase.
- ⁇ 11> The method for ligating nucleic acids according to any one of ⁇ 7> to ⁇ 9>, wherein the cell-derived nucleic acid ligase is cell-derived T4 RNA ligase.
- a method for preparing an NGS library comprising: contacting a cell-derived nucleic acid ligase with a methylated DNA degrading enzyme; ligating a 5'-end adenylated single-stranded DNA as a 3' adapter to each of the 3' ends of a plurality of types of nucleic acids having different sequences using the cell-derived nucleic acid ligase contacted with the methylated DNA degrading enzyme; ligating a single-stranded RNA as a 5' adapter to each of the 5' ends of the plurality of types of nucleic acids; synthesizing cDNA by reverse transcription from the plurality of types of nucleic acids to which the 3' adapter and the 5' adapter have been ligated; and amplifying the obtained cDNA by PCR.
- ⁇ 13> The method for preparing an NGS library according to ⁇ 12>, wherein the methylated DNase is at least one selected from the group consisting of DpnI, McrBC, MspJI, FspEI, LpnPI, and AbaSI.
- ⁇ 14> The method for preparing an NGS library according to ⁇ 12> or ⁇ 13>, wherein the cell-derived nuclease is an Escherichia coli-derived nuclease.
- a kit comprising a cell-derived nuclease and a methyl-DNA degrading enzyme contained in the same container or in separate containers.
- the present disclosure provides a method for preparing a protein sample, a method for ligating nucleic acids, a method for preparing an NGS library, and a kit that can easily stabilize the quality of cell-derived proteins.
- Figure 1 is a graph showing the difference in quantitative values of microRNA between production lots when T4 RNA ligase 2 truncated was used.
- Figure 2 is a graph showing the difference in quantitative values of microRNA between production lots when T4 RNA ligase 2 truncated KQ was used.
- the present disclosure is not limited to the following embodiment.
- the components including element steps, etc.
- the numerical ranges indicated using “to” include the numerical values before and after "to” as the lower and upper limits, respectively.
- the upper or lower limit of one numerical range may be replaced with the upper or lower limit of another numerical range.
- the upper or lower limit of the numerical range may be replaced with a value shown in the examples.
- the content of each component in the composition means the total content of the multiple substances present in the composition, unless otherwise specified.
- the method for preparing a protein sample of the present disclosure includes contacting a cell-derived protein with a methylated DNA enzyme.
- methylated DNA enzyme refers to an enzyme that specifically degrades methylated DNA but does not degrade unmethylated DNA.
- the method for preparing a protein sample according to the present disclosure can simply and easily stabilize the quality of a cell-derived protein by contacting the cell-derived protein with a methylated DNA degrading enzyme.
- the action of the protein sample preparation method of the present disclosure is not clear, but is presumed to be as follows.
- Cell-derived proteins may be contaminated with not only the target protein but also cell-derived DNA (i.e., cell-specific DNA present within the cell).
- Cell-derived DNA generally has methylated bases, that is, it can be said to be methylated DNA. Therefore, when a methylated DNA decomposition enzyme is brought into contact with a cell-derived protein contaminated with methylated DNA, the methylated DNA decomposition enzyme degrades the methylated DNA.
- the cell-derived protein contacted with methylated DNA degrading enzyme when used in a reaction system involving nucleic acid (e.g., DNA or RNA), the inhibition of the activity of the target protein contained in the cell-derived protein by methylated DNA can be reduced, and further, side reactions caused by methylated DNA can also be reduced. From the above, the method for preparing a protein sample disclosed herein can fully ensure the activity of a target protein contained in cell-derived proteins.
- nucleic acid e.g., DNA or RNA
- the amount of cell-derived DNA contaminating a cell-derived protein depends on the culture environment and growth state of the cells. Therefore, cell-derived DNA can cause the activity of a target protein contained in a cell-derived protein to vary depending on the production lot of the protein.
- a cell-derived protein by contacting a cell-derived protein with a methylated DNA decomposition enzyme, similar to the above-mentioned mechanism of action, the cell-derived methylated DNA is decomposed, and the production lot-to-lot difference in the activity of a target protein contained in a cell-derived protein due to the production lot-to-lot difference in the amount of cell-derived DNA contaminating the cell-derived protein can be reduced.
- the method for preparing a protein sample disclosed herein can reduce the difference in activity of a target protein contained in a cell-derived protein between production lots.
- General DNA decomposition enzymes degrade unmethylated DNA.
- a methylated DNA decomposition enzyme is used.
- the following problem occurs. That is, even after the use of the DNA decomposition enzyme, the DNA decomposition enzyme remains in the reaction system, and in the subsequent reaction system involving nucleic acid, a decomposition reaction of DNA required for the main reaction and DNA generated by the main reaction occurs. Therefore, if a general DNA decomposition enzyme is used, a cumbersome task of removing the DNA decomposition enzyme is required.
- methylated DNase does not degrade unmethylated DNA.
- methylated DNase does not inhibit the main reaction involving the nucleic acid.
- the method for preparing a protein sample disclosed herein makes it possible to stabilize the quality of a cell-derived protein, such as by fully ensuring the activity of a target protein contained in the cell-derived protein and by reducing the difference in activity of the target protein contained in the cell-derived protein between production lots. It should be noted that the present disclosure is in no way limited to the above presumed mechanism.
- the type of methylated DNA degrading enzyme in the preparation method of a protein sample of the present disclosure is not particularly limited as long as it has the function of degrading methylated DNA.
- the type of methylated base recognized by the methylated DNA degrading enzyme is also not particularly limited, and a methylated DNA degrading enzyme that recognizes methylated adenine or methylated cytosine is preferred. Only one type of methylated DNA decomposition enzyme may be used, or two or more types may be used.
- the methylated DNA degrading enzyme is preferably at least one selected from the group consisting of DpnI, McrBC, MspJI, FspEI, LpnPI, and AbaSI, more preferably at least one selected from the group consisting of DpnI, McrBC, and MspJI, and even more preferably DpnI.
- the methylated DNAse of the present disclosure may be a mutant of DpnI, McrBC, MspJI, FspEI, LpnPI, or AbaSI.
- a mutant of DpnI, McrBC, MspJI, FspEI, LpnPI, or AbaSI refers to one that has, for example, 85% or more, preferably 90% or more, more preferably 95% or more, even more preferably 98% or more, and particularly preferably 99% or more sequence identity to the amino acid sequence of the wild-type methylated DNA enzyme from which it is derived, and has activity of degrading methylated DNA similar to the wild-type methylated DNA enzyme.
- the method for calculating the identity of amino acid sequences can be carried out by known means.
- the calculation can be carried out using a commercially available analysis tool or an analysis tool available via an electric communication line (Internet), and as one example, the identity of amino acid sequences can be calculated using the homology algorithm BLAST (Basic local alignment search tool) of the National Center for Biotechnology Information (NCBI) http://www.ncbi.nlm.nih.gov/BLAST/ using default (initial setting) parameters.
- BLAST Basic local alignment search tool
- NCBI National Center for Biotechnology Information
- a mutant of methylated DNA enzyme may be a protein consisting of an amino acid sequence in which one or several amino acids have been substituted, deleted, inserted and/or added in the amino acid sequence of the wild-type methylated DNA enzyme from which it is derived, and may have activity of degrading methylated DNA similar to that of the wild-type methylated DNA enzyme.
- "one or several” may be, for example, 1 to 80, preferably 1 to 40, more preferably 1 to 10, even more preferably 1 to 5, and particularly preferably 1 to 3, but is not particularly limited thereto.
- the methylated DNA enzyme may be a commercially available methylated DNA enzyme, such as, but not limited to, DpnI, McrBC, MspJI, FspEI, LpnPI, or AbaSI from New England Biolabs Inc. DpnI may also be commercially available from Takara Bio Inc., Toyobo Co., Ltd., or Nippon Genetics Japan Co., Ltd.
- a "cell-derived protein” is a mixture that may contain not only a target protein possessed by a cell, but also cell-derived DNA and the like. That is, in the present disclosure, "cell-derived” means that it may also include substances derived from cells.
- the cell-derived protein may be a commercially available protein (e.g., T4 RNA ligase 1 or T4 RNA ligase 2 from New England Biolabs Inc.) or a protein obtained by independently culturing cells.
- a commercially available protein e.g., T4 RNA ligase 1 or T4 RNA ligase 2 from New England Biolabs Inc.
- a protein obtained by independently culturing cells e.g., T4 RNA ligase 1 or T4 RNA ligase 2 from New England Biolabs Inc.
- the "cell” in the cell-derived protein is preferably a cell having a DNA methylase gene.
- DNA methylase genes include dam methylase, dcm methylase, CG methylase, DNA methyltransferase 3 alpha, and DNA methyltransferase 3 beta.
- the "cells" in the cell-derived protein may be prokaryotic cells such as bacteria, eukaryotic cells such as yeast cells, filamentous fungal cells, animal cells, and plant cells, and cultured cells derived from these cells. From the viewpoints of rapid growth and reduced culture costs, the "cells" in the cell-derived protein are preferably prokaryotic cells such as bacteria.
- prokaryotes such as bacteria include microorganisms belonging to the genera Escherichia, Brevibacillus, Serratia, Bacillus, Microbacterium, Brevibacterium, Corynebacterium, Lactococcus, and Pseudomonas.
- prokaryotes include the genera Escherichia, Bacillus, Corynebacterium, Lactococcus, and Pseudomonas.
- Escherichia include Escherichia coli
- Bacillus include Bacillus subtilis.
- the "cells" in the cell-derived protein are preferably microorganisms belonging to the genus Escherichia, more preferably Escherichia coli, from the viewpoint of being commonly used in protein synthesis. That is, the cell-derived protein is preferably a protein derived from Escherichia coli.
- yeasts include yeasts belonging to the genera Saccharomyces, Schizosaccharomyces, Kluyveromyces, Trichosporon, Schwanniomyces, Pichia, Candida, Yarrowia, and Hansenula.
- filamentous fungi examples include fungi belonging to the genera Acremonium, Aspergillus, Ustilago, Trichoderma, Neurospora, Fusarium, Humicola, Penicillium, Myceliophtora, Botryts, Magnaporthe, Mucor, Metarhizium, Monascus, Rhizopus, and Rhizobium.
- animal cells include mammalian cells (cells of humans, monkeys, dogs, cats, mice, rats, rabbits, cows, horses, pigs, and sheep, etc.), amphibian cells (cells of frogs, salamanders, tadpoles, and newts, etc.), reptile cells (cells of geckos, lizards, and turtles, etc.), avian cells (cells of chickens and quails, etc.), fish cells (cells of zebrafish and medaka, etc.), and insect cells (cells of fruit flies, silkworms, tobacco hornworms, and honeybees, etc.).
- mammalian cells cells of humans, monkeys, dogs, cats, mice, rats, rabbits, cows, horses, pigs, and sheep, etc.
- amphibian cells cells of frogs, salamanders, tadpoles, and newts, etc.
- reptile cells cells of geckos, lizards
- Plant cells include, for example, cells of cereals (cells of rice, wheat, corn, etc.), cells of commercial crops (cells of tomato, cucumber, eggplant, etc.), cells of horticultural plants (cells of carnation and lisianthus, etc.), and cells of experimental plants (cells of tobacco and Arabidopsis, etc.).
- the "protein” in cell-derived proteins include enzymes, chromoproteins, membrane proteins, transport proteins, structural proteins, motor proteins, binding proteins, receptor proteins, antibody proteins, and regulatory proteins.
- the "protein” in the cell-derived protein is preferably an enzyme, from the viewpoint that the protein sample obtained by the method for preparing a protein sample of the present disclosure can be used in a reaction system involving nucleic acid, etc.
- the cell-derived protein is preferably an enzyme derived from a cell.
- cell-derived enzymes include oxidoreductases, transferases, hydrolases, lyases, isomerases, synthetic enzymes (ligases or synthetases), and translocases.
- the cell-derived enzyme is preferably a synthetic enzyme, more preferably a ligase (also called ligase), and even more preferably a nucleic acid ligase. That is, the cell-derived protein is preferably a cell-derived nucleic acid ligase.
- the cell-derived nucleic acid ligase is more preferably an Escherichia coli-derived nucleic acid ligase.
- nucleic acid ligases examples include DNA ligases and RNA ligases.
- DNA ligases examples include T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, E. coli DNA ligase, Taq DNA ligase, and 9°N DNA ligase.
- RNA ligases examples include T4 RNA ligase, and examples of T4 RNA ligases include T4 RNA ligase 1 and T4 RNA ligase 2.
- the cell-derived enzyme is preferably T4 RNA ligase 2, more preferably T4 RNA ligase 2 truncated, T4 RNA ligase 2 truncated KQ, or T4 RNA Ligase 2 truncated K227Q, and even more preferably T4 RNA ligase 2 truncated or T4 RNA ligase 2 truncated KQ.
- T4 RNA ligase 2 truncated is a mutant in which the C-terminus of the amino acid sequence of T4 RNA ligase 2 is deleted, and generally has the 1st to 249th amino acids of the N-terminus of T4 RNA ligase 2.
- T4 RNA ligase 2 truncated K227Q is a mutant in which K (lysine) at position 227 in the amino acid sequence of T4 RNA ligase 2 truncated is mutated to Q (glutamine).
- T4 RNA ligase 2 truncated KQ is a mutant (double point mutant) in which the 55th R (arginine) is mutated to K (lysine) in the amino acid sequence of T4 RNA ligase 2 truncated K227Q.
- the protein sample obtained by the method for preparing a protein sample of the present disclosure is a mixture containing the target protein possessed by the cell, methylated DNA decomposition enzyme, and DNA derived from the cell decomposed by the methylated DNA decomposition enzyme.
- the protein sample obtained by the method for preparing a protein sample of the present disclosure contains not only the target protein possessed by the cell, but also the methylated DNA decomposition enzyme.
- the methylated DNA decomposition enzyme does not decompose unmethylated DNA.
- the methylated DNA decomposition enzyme does not inhibit the main reaction involving the nucleic acid.
- ⁇ Preparation Method> In the method for preparing a protein sample of the present disclosure, the details of the method are not particularly limited as long as it is possible to contact a methylated DNA enzyme with a cell-derived protein.
- Contacting the cell-derived protein with the methylated DNase may be, for example, adding the methylated DNase to the cell-derived protein, adding the cell-derived protein to the methylated DNase, or mixing the cell-derived protein with the methylated DNase. Contacting the cell-derived protein with the methylated DNase may be carried out in a reaction solution containing water.
- the reaction solution may further contain a metal ion.
- the metal ion include magnesium ion, zinc ion, iron ion, copper ion, manganese ion, calcium ion, etc.
- the metal ions magnesium ion is preferable.
- the reaction solution may further contain, for example, EDTA (ethylenediaminetetraacetic acid), glycerol, ATP (adenosine triphosphate), ammonium sulfate, PEG (polyethylene glycol), an RNase inhibitor, potassium chloride, sodium chloride, Tris-HCl, magnesium chloride, or dithiothreitol (DTT).
- the concentration of each substance in the reaction solution is not particularly limited, and can be determined by varying the amount of methylated DNA enzyme added to the cell-derived protein and evaluating the effect of the cell-derived protein. From the viewpoint of promoting the action of methylated DNA enzyme, it is preferable that the reaction solution contains 0.1 to 50 mM Mg 2+ .
- the temperature at which the methylated DNA degrading enzyme is brought into contact with the cell-derived protein is preferably 20°C to 50°C, more preferably 30°C to 45°C, even more preferably 35°C to 40°C, particularly preferably 36°C to 38°C, and most preferably 37°C.
- the lower limit of the contact time is preferably 5 minutes or more, more preferably 10 minutes or more, even more preferably 20 minutes or more, and particularly preferably 30 minutes or more.
- the upper limit of the contact time is not particularly limited, but may be 5 hours, 3 hours, or 1 hour.
- the nucleic acid ligation method of the present disclosure comprises: contacting a methylated DNA degrading enzyme with a cell-derived nucleic acid ligase; ligating a second nucleic acid to a first nucleic acid using the cell-derived nucleic acid ligase contacted with the methylated DNA degrading enzyme; Includes.
- ⁇ Contact> For an explanation of contacting a cell-derived nucleic acid ligase with a methylated DNA enzyme in the nucleic acid ligation method of the present disclosure, including definitions, examples, preferred aspects, etc., please refer to the explanation of "Contacting a cell-derived protein with a methylated DNA enzyme" described in the section "Method for preparing a protein sample.”
- the methylated DNA enzyme is preferably at least one selected from the group consisting of DpnI, McrBC, MspJI, FspEI, LpnPI, and AbaSI, more preferably at least one selected from the group consisting of DpnI, McrBC, and MspJI, and even more preferably DpnI.
- the cell-derived nucleic acid ligase is preferably an Escherichia coli-derived nucleic acid ligase.
- the cell-derived nucleic acid ligase include cell-derived DNA ligase or RNA ligase.
- the DNA ligase include T3 DNA Ligase, T4 DNA Ligase, T7 DNA Ligase, E. coli DNA Ligase, Taq DNA Ligase, and 9°N DNA Ligase.
- the RNA ligase include T4 RNA Ligase, and examples of the T4 RNA Ligase include T4 RNA ligase 1 or T4 RNA ligase 2.
- the cell-derived nucleic acid ligase is preferably cell-derived T4 RNA ligase 2, more preferably cell-derived T4 RNA ligase 2 truncated, T4 RNA ligase 2 truncated KQ, or T4 RNA Ligase 2 truncated K227Q, and even more preferably cell-derived T4 RNA ligase 2 truncated or T4 RNA ligase 2 truncated KQ.
- the second nucleic acid is ligated to the first nucleic acid using a cell-derived nucleic acid ligase contacted with a methylated DNA degrading enzyme, and the detailed conditions can be those of a conventional method.
- concentration of each component, temperature, time, etc., when the second nucleic acid is ligated to the first nucleic acid are not particularly limited.
- the first nucleic acid and the second nucleic acid may each independently be DNA, RNA, an analog thereof, or a fusion thereof.
- the nucleic acid may be small RNA (sRNA).
- the small RNA may be any of microRNA (miRNA), piRNA, and tsRNA.
- the nucleic acid may be a nucleic acid composed only of the bases A, T, G, C, and U, or may not be a nucleic acid composed only of the bases A, T, G, C, and U.
- the first and second nucleic acids are nucleic acids that are not substrates for the methylated DNA degrading enzyme used. Combinations of the first and second nucleic acids include combinations of multiple types of nucleic acids with different sequences and a 3' adapter, and combinations of multiple types of nucleic acids with different sequences and a 5' adapter, as described below.
- the nucleic acid ligation method disclosed herein can be used for applications such as preparing NGS libraries, preparing samples for qPCR, and cloning.
- the method for preparing an NGS library of the present disclosure includes: contacting a methylated DNA degrading enzyme with a cell-derived nucleic acid ligase; ligating a 5'-terminal adenylated single-stranded DNA, which is a 3' adapter, to the 3' end of each of a plurality of types of nucleic acids having different sequences, using the cell-derived nucleic acid ligase that has been contacted with the methylated DNA degrading enzyme; ligating a single-stranded RNA as a 5' adaptor to the 5' end of each of the plurality of types of nucleic acids; synthesizing cDNA from the multiple types of nucleic acids to which the 3' adaptor and the 5' adaptor have been ligated by a reverse transcription reaction; amplifying the obtained cDNA by PCR; Includes.
- ⁇ Contact> For an explanation of contacting a cell-derived nucleic acid ligase with a methylated DNA enzyme in the method for preparing an NGS library of the present disclosure, including definitions, examples, and preferred aspects, please refer to the explanation of "Contacting a cell-derived protein with a methylated DNA enzyme" in the section titled “Method for preparing a protein sample.”
- the methylated DNA enzyme is preferably at least one selected from the group consisting of DpnI, McrBC, MspJI, FspEI, LpnPI, and AbaSI, more preferably at least one selected from the group consisting of DpnI, McrBC, and MspJI, and even more preferably DpnI.
- the cell-derived nucleic acid ligase is preferably an Escherichia coli-derived nucleic acid ligase.
- the cell-derived nucleic acid ligase include cell-derived DNA ligase or RNA ligase.
- the DNA ligase include T3 DNA Ligase, T4 DNA Ligase, T7 DNA Ligase, E. coli DNA Ligase, Taq DNA Ligase, and 9°N DNA Ligase.
- the RNA ligase include T4 RNA Ligase, and examples of the T4 RNA Ligase include T4 RNA ligase 1 or T4 RNA ligase 2.
- the cell-derived nucleic acid ligase is preferably cell-derived T4 RNA ligase 2, more preferably cell-derived T4 RNA ligase 2 truncated, T4 RNA ligase 2 truncated KQ, or T4 RNA Ligase 2 truncated K227Q, and even more preferably cell-derived T4 RNA ligase 2 truncated or T4 RNA ligase 2 truncated KQ.
- the method for preparing an NGS library according to the present disclosure includes ligating a 5'-terminal adenylated single-stranded DNA as a 3' adapter to the 3' end of each of multiple types of nucleic acids having different sequences, using a cell-derived nucleic acid ligase that has been contacted with a methylated DNA degrading enzyme.
- multiple types of nucleic acids having different sequences means that there are multiple types of nucleic acids having different base sequences.
- the form of the multiple types of nucleic acids having different sequences is not particularly limited.
- the nucleic acid is preferably single-stranded from the viewpoint of easy ligation with the 5'-end adenylated single-stranded DNA described later.
- the nucleic acid may be, for example, DNA, RNA, an analog thereof, or a fusion thereof.
- the nucleic acid may be small RNA (sRNA).
- the small RNA may be any of microRNA (miRNA), piRNA, and tsRNA.
- the nucleic acid may be a nucleic acid composed only of bases A, T, G, C, and U, and may not be a nucleic acid composed only of bases A, T, G, C, and U.
- Specific examples of nucleic acids not composed only of bases A, T, G, C, and U include modified DNA or RNA such as methylation (but only those that are not degraded by the methylated DNA degrading enzyme used) or nucleic acids that have been edited such as A-to-I RNA editing.
- the nucleic acid is one that is not a substrate for the methylated DNAse used.
- the origin of the nucleic acid is not particularly limited, and may be a naturally-derived nucleic acid (e.g., total RNA) or a synthetic RNA.
- the origin of the nucleic acid may be, for example, a biological sample, a virus sample, an environmental sample, or an artificial sample.
- Biological samples include samples derived from animals, plants, fungi, bacteria, etc.
- Animals include humans and non-human animals, etc.
- Non-human animals include non-human mammals (e.g., monkeys, dogs, cats, mice, rats, rabbits, cows, horses, pigs, sheep, etc.) and birds (chickens, quails, etc.).
- samples derived from animals include serum, plasma, whole blood, urine, feces, saliva, bone marrow fluid, lymphatic fluid, and tissues.
- samples derived from soil or water include samples derived from soil or water.
- samples derived from soil or water include samples derived from soil or water.
- artificial samples include artificial serum, artificial plasma, and artificial urine.
- the nucleic acid may be 10,000 to 300,000 types of nucleic acid, 10,000 to 10,000 types of nucleic acid, or 1 to 2,000 types of nucleic acid.
- the base length of the nucleic acid is not particularly limited, but is preferably 1 to 100 bases long, more preferably 10 to 50 bases long, and even more preferably 16 to 40 bases long.
- the 3' adaptor is a 5'-end adenylated single-stranded DNA.
- the 5'-end adenylated single-stranded DNA is a single-stranded DNA in which the 5'-terminal nucleotide is adenylated.
- the first and subsequent bases of the 5'-terminal base sequence may be any base sequence.
- the first and subsequent bases of the 5'-terminal base sequence, excluding the adenylic acid at the 5'-terminal may contain modified bases. Examples of modified bases include, but are not limited to, 4-acetylcytidine, dihydrouridine, inosine, 1-methyladenosine, and the like (but limited to those that are not degraded by the methylated DNA degrading enzyme used).
- the 3' adaptor is a nucleic acid that is not a substrate for the methylating DNase used.
- the length of the 3' adapter is preferably 6 to 1000 bases, more preferably 6 to 100 bases, and even more preferably 10 to 30 bases.
- the 3'-terminal nucleotide of the 3' adaptor is preferably modified with a compound having a modification structure capable of suppressing the binding of nucleic acid.
- Compounds having a modified structure capable of inhibiting the binding of nucleic acids include dideoxyribonucleoside triphosphates (ddNTPs) and amino groups.
- dideoxyribonucleoside triphosphates include dideoxycytidine triphosphate (ddCTP), dideoxyguanosine triphosphate (ddGTP), dideoxythymidine triphosphate (ddTTP), and dideoxyadenosine triphosphate (ddATP).
- dideoxyribonucleoside triphosphate is preferable, and dideoxycytidine triphosphate is more preferable.
- the detailed conditions for ligating a 5'-end adenylated single-stranded DNA as a 3' adapter to the 3' end of each of a plurality of types of nucleic acids having different sequences can be in accordance with a conventional method.
- concentration of each component, temperature, time, etc. during ligation are not particularly limited.
- the reaction temperature when ligating the 5'-end adenylated single-stranded DNA, which is the 3' adapter, to the 3' ends of multiple types of nucleic acids with different sequences is preferably 10°C to 40°C, more preferably 15°C to 30°C, even more preferably 17°C to 25°C, and particularly preferably 20°C.
- the reaction time is preferably 10 minutes to 2 hours, more preferably 30 minutes to 90 minutes, even more preferably 45 minutes to 75 minutes, and particularly preferably 1 hour.
- 3' adapter may be ligated to the 3' end of the nucleic acid, or two or more types of 3' adapters may be ligated.
- the 5' adapter may be ligated using a cell-derived nucleic acid ligase that has been contacted with the methylated DNA degrading enzyme, or other known nucleic acid ligases.
- the detailed conditions for ligating a single-stranded RNA as a 5' adaptor to the 5' end of each of the multiple types of nucleic acids can be in accordance with a conventional method.
- concentration of each component, temperature, time, etc. during ligation are not particularly limited.
- the reaction temperature when ligating the single-stranded RNA 5' adapter to the 5' end of each of the multiple types of nucleic acids is preferably 10°C to 40°C, more preferably 15°C to 30°C, even more preferably 17°C to 25°C, and particularly preferably 20°C.
- the reaction time is preferably 10 minutes to 2 hours, more preferably 30 minutes to 90 minutes, even more preferably 45 minutes to 75 minutes, and particularly preferably 1 hour.
- One type of 5' adapter may be ligated to the 5' end of the nucleic acid, or two or more types of 5' adapters may be ligated.
- the method for preparing an NGS library according to the present disclosure includes synthesizing cDNA by reverse transcription reaction from the multiple types of nucleic acids to which the 3' adaptor and the 5' adaptor have been ligated.
- the reverse transcription reaction includes annealing a reverse transcription primer to the multiple types of nucleic acids to which the 3' adapter and the 5' adapter have been ligated.
- the reverse transcription primer may have a sequence that further adds a unique sequence to each of the multiple types of nucleic acids. Examples of the unique sequence include a UMI (Unique Molecular Identifier) sequence.
- the method of reverse transcription reaction for synthesizing cDNA is not particularly limited, and for example, known reverse transcriptase and conditions for reverse transcription reaction can be used.
- the reverse transcription reaction can be performed by reverse transcribing the multiple types of nucleic acids to which the 3' adapter and 5' adapter have been ligated in the presence of reverse transcriptase, primer, dNTP mix, and an appropriate buffer.
- the disclosed method for preparing an NGS library includes amplifying the obtained cDNA by PCR.
- the PCR method is not particularly limited, and known PCR enzymes and PCR conditions can be used, provided that the PCR product is not a substrate for the methylated DNA degrading enzyme used.
- the method for preparing an NGS library of the present disclosure includes: contacting a methylated DNA degrading enzyme with a cell-derived nucleic acid ligase; ligating a 5'-terminal adenylated single-stranded DNA, which is a 3' adapter, to the 3' end of each of a plurality of types of nucleic acids having different sequences, using the cell-derived nucleic acid ligase that has been contacted with the methylated DNA degrading enzyme; ligating a single-stranded RNA as a 5' adaptor to the 5' end of each of the plurality of types of nucleic acids; synthesizing cDNA from the multiple types of nucleic acids to which the 3' adaptor and the 5' adaptor have been ligated by a reverse transcription reaction; amplifying the obtained cDNA by PCR, in this order.
- ligating a single-stranded RNA that is a 5' adapter to the 5' end of each of the multiple types of nucleic acids means ligating a single-stranded RNA that is a 5' adapter to the 5' end of each of the multiple types of nucleic acids to which the 3' adapter has been ligated.
- ligating 5'-terminal adenylated single-stranded DNA as a 3' adapter to the 3' end of each of the multiple types of nucleic acids means ligating 5'-terminal adenylated single-stranded DNA as a 3' adapter to the 3' end of each of the multiple types of nucleic acids to which the 5' adapter has been ligated.
- Kit The kit of the present disclosure includes a cell-derived nuclease and a methyl-DNA degrading enzyme contained in the same container or in separate containers.
- cell-derived nucleic acid ligase and methylated DNA degrading enzyme in the kit of the present disclosure, including definitions, examples, and preferred embodiments, is the same as the explanation of the "cell-derived nucleic acid ligase" and "methylated DNA degrading enzyme” described in the section "Method for preparing protein samples.”
- the container may contain a buffer for stably storing the cell-derived nucleic acid ligase or methylated DNA degrading enzyme.
- a buffer for stably storing the cell-derived nucleic acid ligase or methylated DNA degrading enzyme.
- components contained in the buffer include Tris-HCl, Triton (registered trademark) X, potassium chloride, sodium chloride, dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA), bovine serum albumin (BSA), and glycerol.
- the kit of the present disclosure may further include at least one selected from the group consisting of a 3' adaptor, a 5' adaptor, a reverse transcriptase, a reverse transcription primer, a PCR enzyme, and a PCR primer, each of which is stored in a separate container.
- the reverse transcriptase, reverse transcription primer, PCR enzyme, and PCR primer may be any known enzyme.
- hsa-miR-10a-5p hsa-miR-155-5p, hsa-miR-106b-3p, hsa-miR-320d, hsa-miR-340-3p, hsa-miR-107, hsa-miR-432-5p, hsa-miR-744 -5p, hsa-miR-181b-5p, hsa-miR-103a-3p, hsa-miR-4446-3p, hsa-miR-223-3p, hsa-let-7d-3p, hsa-miR-652-3p, hsa-miR-24-2-5p, hsa-miR-16-2-3p, hsa-miR-1307-3p, hsa-miR-106a-5p, hsa-miR-340-5p, hsa-miR
- T4 RNA ligase 2 truncated KQ available from New England Biolabs Inc. (NEB) is a cell-derived protein. Preparation of protein samples, preparation of NGS libraries, and sequencing were performed in the same manner as in ⁇ Experiment 1>, except that the nucleic acid ligase in ligating the 3' adapter was changed to T4 RNA ligase 2 truncated KQ.
- the top 30 types of microRNAs that are significantly affected by lot-to-lot differences when not treated with DpnI are as follows.
- hsa-miR-363-3p hsa-miR-24-2-5p, hsa-miR-191-5p, hsa-miR-379-5p, hsa-miR-10a-5p, hsa-miR-16-2-3p, hsa-miR-4446-3p, hsa- let-7d-3p, hsa-miR-1246, hsa-miR-30c-5p, hsa-miR-432-5p, hsa-miR-152-3p, hsa-miR-30e-5p, hsa-miR-18a-5p, hsa-miR-28-5p, hsa-miR-320d, hsa-miR-340-3p, hsa-miR-107, hsa-miR-125a-5p, hsa-miR-20a-5p,
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025551492A JPWO2025079564A1 (cg-RX-API-DMAC7.html) | 2023-10-13 | 2024-10-07 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177842 | 2023-10-13 | ||
| JP2023-177842 | 2023-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2025079564A1 true WO2025079564A1 (ja) | 2025-04-17 |
Family
ID=95395591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2024/035866 Ceased WO2025079564A1 (ja) | 2023-10-13 | 2024-10-07 | タンパク質試料の調製方法、核酸のライゲーション方法、ngsライブラリの調製方法、及びキット |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2025079564A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2025079564A1 (cg-RX-API-DMAC7.html) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140018264A1 (en) * | 2010-11-03 | 2014-01-16 | Illumina, Inc. | Reducing adapter dimer formation |
| US20150072870A1 (en) * | 2010-09-10 | 2015-03-12 | New England Biolabs, Inc. | Method for Reducing Adapter-Dimer Formation |
| JP2017079735A (ja) * | 2015-10-28 | 2017-05-18 | 大韓民国行政自治部国立科学捜査研究院 | Ngsライブラリ作製用プライマーセットおよびこれを用いたngsライブラリ作製法およびキット |
| JP2017518048A (ja) * | 2014-06-05 | 2017-07-06 | キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dna増幅反応の最適化 |
| JP2020103230A (ja) * | 2018-12-28 | 2020-07-09 | 東洋紡株式会社 | アダプターダイマーの生成抑制方法 |
| JP2022131985A (ja) * | 2021-02-26 | 2022-09-07 | ジニナス株式会社 | 分子バーコディング効率を向上させるための組成物及びその用途 |
| JP2023525880A (ja) * | 2020-05-15 | 2023-06-19 | インテグレイテッド ディーエヌエー テクノロジーズ, インコーポレイテッド | ライゲーションカップルドpcrの方法 |
-
2024
- 2024-10-07 JP JP2025551492A patent/JPWO2025079564A1/ja active Pending
- 2024-10-07 WO PCT/JP2024/035866 patent/WO2025079564A1/ja not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150072870A1 (en) * | 2010-09-10 | 2015-03-12 | New England Biolabs, Inc. | Method for Reducing Adapter-Dimer Formation |
| US20140018264A1 (en) * | 2010-11-03 | 2014-01-16 | Illumina, Inc. | Reducing adapter dimer formation |
| JP2017518048A (ja) * | 2014-06-05 | 2017-07-06 | キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dna増幅反応の最適化 |
| JP2017079735A (ja) * | 2015-10-28 | 2017-05-18 | 大韓民国行政自治部国立科学捜査研究院 | Ngsライブラリ作製用プライマーセットおよびこれを用いたngsライブラリ作製法およびキット |
| JP2020103230A (ja) * | 2018-12-28 | 2020-07-09 | 東洋紡株式会社 | アダプターダイマーの生成抑制方法 |
| JP2023525880A (ja) * | 2020-05-15 | 2023-06-19 | インテグレイテッド ディーエヌエー テクノロジーズ, インコーポレイテッド | ライゲーションカップルドpcrの方法 |
| JP2022131985A (ja) * | 2021-02-26 | 2022-09-07 | ジニナス株式会社 | 分子バーコディング効率を向上させるための組成物及びその用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2025079564A1 (cg-RX-API-DMAC7.html) | 2025-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102339365B1 (ko) | 키메라 게놈 조작 분자 및 방법 | |
| KR102435352B1 (ko) | 리가제-연관 핵산 원형화 및 증폭 | |
| EP2712931B1 (en) | Immobilized transposase complexes for DNA fragmentation and tagging | |
| EP2396430B1 (en) | Template-independent ligation of single-stranded dna | |
| US20160017393A1 (en) | Directed endonucleases for repeatable nucleic acid cleavage | |
| KR20200036925A (ko) | 이중-가닥 콘카테머 dna를 사용하는 무세포 단백질 발현 | |
| JP2022511207A (ja) | ブリッジ増幅によるクラスタ生成のための方法および組成物 | |
| CN120153070A (zh) | 解旋酶-胞苷脱氨酶复合物及其使用方法 | |
| US20240287484A1 (en) | Systems, compositions, and methods involving retrotransposons and functional fragments thereof | |
| KR20210106880A (ko) | 폴리뉴클레오티드 클러스터 클론형성능 우선성을 개선하는 방법 | |
| CA3167758A1 (en) | Methods of sample normalization | |
| US20190040397A1 (en) | Method for producing dna vectors from molecular bricks containing sequences of interest | |
| JP5652843B2 (ja) | Dna増幅法 | |
| US20220162592A1 (en) | Duplex-specific nuclease depletion for purification of nucleic acid samples | |
| US20150167065A1 (en) | Isothermal amplification of nucleic acids within a porous matrix | |
| WO2025079563A1 (ja) | 5'末端アデニル化一本鎖dnaの分解方法、3'アダプターの核酸へのライゲーション方法、ngsライブラリの調製方法、ngsライブラリ調製キット、及び核酸ライブラリ調製用3'アダプター | |
| WO2025079565A1 (ja) | ライゲーション方法、アダプターダイマー形成の抑制方法、ngsライブラリの調製方法、ngsライブラリ調製キット、及び3'アダプター | |
| US20250084484A1 (en) | Methods and compositions for transcriptome analysis | |
| US20240360477A1 (en) | Systems and methods for transposing cargo nucleotide sequences | |
| US20250163407A1 (en) | Methods selectively depleting nucleic acid using rnase h | |
| US20260085308A1 (en) | Methods for generating cdna library from rna | |
| WO2012150455A1 (en) | Sensitive preparation and amplification of eukaryotic derived nucleic acid for transcriptional profiling | |
| Jagdish | The CCHC Motif In Non-LTR Retrotransposons Modulates RNA Associated Protein Conformational Changes | |
| EP3412777A1 (en) | Method for measuring target dna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24877159 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2025551492 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2025551492 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |